AstraZeneca has briefed councillors on their plans to build a new office and conference centre at the Cambridge Biomedical ...

AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U ...

An important point about the updated guidelines is the emphasis on individualized treatment of complicated UTIs, recognizing ...

The decline in the company's share price came as its shares traded ex-date following the announcement of a ₹32 per share ...

U.S. bank Wells Fargo has suspended all travel to China after one of its employees was barred from leaving the country, a ...

Groundbreaking findings from Malaysia’s Heart2Miss heart failure screening programme were presented at the European Society ...

U.S. bank Wells Fargo has suspended all travel to China after one of its employees was barred from leaving the country, ...

Astrazeneca (AZN) closed the most recent trading day at $69.26, moving 1.17% from the previous trading session.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical ...

AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical ...

Following a successful patent defense case upheld by China’s IP authority, AstraZeneca invested nearly 9 billion yuan ($1.24 billion) to establish two global R&D centres in Beijing and Shanghai, said ...